Visual summary
Potential long-term benefit must be weighed against hyperkalemia and other adverse effects. Monitoring is part of treatment, not an optional extra.
Text version
Receptor-mediated effects
Mineralocorticoid receptor activation contributes to sodium retention, inflammation, and fibrosis. Blocking this pathway has different evidence across cardiac and kidney populations.
Identify the indication
Heart failure phenotype, resistant hypertension, albuminuric diabetic CKD, and potassium risk determine whether a particular agent is appropriate.
Choose the agent for the studied indication
Spironolactone or eplerenone for appropriate heart-failure or resistant-hypertension indications is a different decision from finerenone for albuminuric diabetic CKD. Review potassium, kidney function, other RAAS drugs, NSAIDs, and supplements before starting; do not substitute agents solely because all block the same receptor.
Plan surveillance before prescribing
For finerenone, measure potassium and kidney function before initiation and reassess potassium at about 4 weeks after starting or changing dose, then periodically. More frequent checks may be needed with illness or interacting drugs. Use the agent-specific eligibility and hold/restart rules.
Interpret trial outcomes accurately
Separate albuminuria changes from hard kidney or cardiovascular outcomes. Confirm that a cited study tested the named drug in the relevant population.
Balance protection and toxicity
Potential long-term benefit must be weighed against hyperkalemia and other adverse effects. Monitoring is part of treatment, not an optional extra.